Research use only. Nothing on this page is medical advice, and pancragen isn’t approved for human use.
Pancragen is a four-amino-acid peptide, Lys-Glu-Asp-Trp (KEDW), developed by Vladimir Khavinson’s group for the pancreas. Nine papers exist, all from that group and its collaborators: cell cultures, rats, old monkeys and one small study of 33 older people with type 2 diabetes. No independent trial exists, FDA hasn’t approved it, and the studies that name the structure used a C-terminal amide while the vial listing we checked gives the free acid.
- Sequence
- Lys-Glu-Asp-Trp (KEDW), a tetrapeptide from Vladimir Khavinson’s group
- Claimed target
- The pancreas
- Papers
- 9, all from Khavinson’s group and collaborators: cells, rats, old monkeys and one small human study (4)
- Independent trials
- None found (11)
- Form in the studies
- Two papers name a C-terminal amide (Lys-Glu-Asp-Trp-NH2) (3, 6)
- Form on sale
- SwissChems lists the free-acid formula, C26H36N6O9 (10)
- FDA status
- Not approved. Not on FDA’s compounding-risk page or in HHS’s October 2026 policy (12, 13)
- WADA 2026
- S0 catch-all for unapproved substances (14)
What is pancragen?
Pancragen, sometimes spelled pancragene, is a synthetic tetrapeptide of lysine, glutamate, aspartate and tryptophan. It belongs to Khavinson’s cytogens, short peptides said to regulate one organ each. Our Khavinson peptides guide covers the family and the evidence behind it.
Two other products share the name. PancraGEN is a molecular test for pancreatic cysts from a diagnostics company and has nothing to do with this peptide. In Russia a capsule supplement sold under the Pancragen name is a different format from a research vial.
Pancragen studies: every paper and what it found
How to read the table. Limited: one small human study from the same group. Monkeys, Rats, Cells: animal or lab work only.
| Study | Model | What it reported | Watch-out |
|---|---|---|---|
| 1Zakutskii, 2006Organ cultures from young and old rats | RatsPancragen stimulated pancreatic explants at a very low concentration, alongside cardiogen, bronchogen and prostamax (1) | Tissue culture, not a living animal | |
| 2Kvetnoi, 2007Rats with experimental diabetes | RatsChanged pancreatic morphology and function (2) | Abstract gives no numbers | |
| 3Khavinson, 2007Streptozotocin diabetic rats | RatsOral pancragen lowered blood glucose during treatment. Injected pancragen normalized capillary endothelial adhesion but not permeability (3) | Early-stage diabetes model. Uses the amide form | |
| 4Korkushko, 201130 healthy and 33 type 2 diabetic older people | LimitedPancragen lowered fasting glucose, glucose tolerance test values, insulin and the insulin resistance index. Patients not given it showed no change. Nocturnal melatonin was 70% lower in diabetics (4) | Same group. The abstract states no randomization or blinding. The melatonin result shows a deficit, not a fix | |
| 5Khavinson, 2012Human embryonic pancreatic cell cultures | CellsRaised CXCL12 and Hoxa3, more in aged cultures (5) | Fetal cells, not adult islets | |
| 6Khavinson, 2012Aged human pancreatic cell cultures | CellsRaised MMP2, MMP9, serotonin, CD79α, Mcl1, PCNA and Ki-67, and lowered p53 (6) | More proliferation and less p53 isn’t proof of benefit. Uses the amide form | |
| 7Khavinson, 2013Young and aged pancreatic cultures | CellsRaised Pdx1 and Ptf1a in acinar cells, and Pdx1, Pax6, Pax4, Foxa2 and Nkx2.2 in islet cells (7) | Marker changes, not new working beta cells | |
| 8Goncharova, 2014Old female rhesus monkeys | MonkeysA 10-day injection course sped glucose clearance and normalized insulin and C-peptide responses. The effect partly lasted 3 weeks (8) | Small study, no independent copy | |
| 9Goncharova, 20159 old female rhesus monkeys, versus glimepiride | MonkeysBoth lowered basal glucose. Pancragen also normalized insulin and C-peptide, and glimepiride acted more strongly with a delayed drop (9) | 5 monkeys on pancragen, 4 on glimepiride |
The two monkey studies are the most striking results, and the 2011 study is the only human data. All nine papers are from Khavinson’s group or its collaborators, and ClinicalTrials.gov lists no registered pancragen trial (11).
Does pancragen lower blood sugar?
In rats and old rhesus monkeys it did, and in one small human study glucose fell. The 2011 study followed 33 older people with type 2 diabetes. Pancragen lowered fasting glucose, glucose tolerance test values, insulin and the insulin resistance index, and patients not given it showed no change (4). That group ran the study of its own product, and the abstract describes no randomization or blinding.
Does pancragen work for type 1 diabetes?
No human data exist. The rat work used streptozotocin, a toxin that damages insulin-producing cells (3). The human study enrolled people with type 2 diabetes (4).
How might pancragen work?
Khavinson’s theory is that short peptides enter the cell nucleus and switch tissue-specific genes back on (15). For pancragen, the cell papers report higher levels of pancreatic differentiation factors such as Pdx1, Ptf1a, Pax6, Pax4, Foxa2 and Nkx2.2 in young and aged cultures (7). They also report more proliferation markers and less p53 in aged cultures (6).
Those are changes in markers. They don’t show new working beta cells, and no paper shows how the peptide reaches the nucleus. Lower p53 and more proliferation could cut either way, because p53 helps protect against cancer.
Is the vial the same pancragen the studies used?
Often it isn’t the same molecule, or nobody knows. The 2007 rat study and a 2012 cell study name the structure as Lys-Glu-Asp-Trp-NH2, an amide at the C-terminal end (3, 6). The other papers write only Lys-Glu-Asp-Trp. SwissChems’ 20 mg listing gives C26H36N6O9, which is the free acid (10).
| Form | Formula | Where it appears | What is known |
|---|---|---|---|
| 1C-terminal amide (KEDW-NH2) | Lys-Glu-Asp-Trp-NH2, C26H37N7O8 by calculation | Named in the 2007 rat study and a 2012 cell study (3, 6) | The form the structure-naming papers describe |
| 2Free acid (KEDW-OH) | Lys-Glu-Asp-Trp, C26H36N6O9, 576.25 g/mol | The formula on SwissChems’ 20 mg listing (10) | No study compares it with the amide |
| 3Name only | “Lys-Glu-Asp-Trp” | The 2013 paper and both monkey papers (7, 8, 9) | These abstracts don’t state the end group |
Nobody has compared the two forms, so it is wrong to call either one inactive. The practical rule is to ask the seller which end group the vial has, and to look for mass spectrometry on the certificate. The amide is about 1 Da lighter than the acid, so identity data can tell them apart.
Where to buy pancragen
SwissChems lists a 20 mg pancragen vial. Nextchems shows no pancragen product, and no other seller we could check lists one.
SwissChems
Pancragen 20 mg · $59.95, list $65
- Lists formula C26H36N6O9 and 576.25 g/mol, the free-acid form
- States independent third-party HPLC testing and a COA per batch, with a lab-report link on the page
- 30-day returns on unopened products; same-day US shipping before 12 PM EST
Check the certificate before you rely on any vial. Our guide to verifying a peptide COA explains each line, and best peptide vendors compares sellers by what their lab reports show.
Pancragen dosage: is there one?
No dose is established, because no independent trial exists. The studies used short courses. The monkey work was a 10-day injection course (8, 9). A seller’s 20 mg vial holds hundreds of times the microgram-scale amounts those animals received, so vial size says nothing about a dose, and the schedules on forums and seller pages don’t come from the studies.
Pancragen side effects and safety
No human safety data beyond a short abstract exist. The 2011 abstract reports no adverse events, which describes the reporting and doesn’t show the peptide is free of side effects. No toxicology, pharmacokinetic or interaction studies were found.
- Glucose lowering. If pancragen lowers glucose in people, it could add to the effect of insulin, sulfonylureas or other diabetes medicines, and the 2015 monkey study compared it with glimepiride (9). Don’t change prescribed medicine for an experimental peptide.
- Growth and cell-death markers. More Ki-67 and PCNA and less p53 in cell cultures are signals worth studying, not benefits (6).
- Product quality. Gray-market vials vary, and the form on the label may not match the studies.
Pregnant or breastfeeding women, people with diabetes on medication and tested athletes should avoid it.
Is pancragen approved or legal?
No. FDA hasn’t approved pancragen, and it doesn’t appear on FDA’s list of bulk substances that may present significant safety risks (12). HHS’s 28 October 2026 interim policy covers six other peptides, not pancragen, and it excludes research chemicals and supplements anyway (13). WADA’s 2026 List bans any substance without regulatory approval under S0 (14).
Pancragen FAQ
What is pancragen peptide?
Pancragen is the synthetic tetrapeptide Lys-Glu-Asp-Trp (KEDW), developed by Vladimir Khavinson’s group and studied for the pancreas. It has no approved use.
Does pancragen lower blood sugar?
In rats and old rhesus monkeys it did. In one small 2011 study of 33 older people with type 2 diabetes, fasting glucose and insulin fell. All the evidence comes from the same research group.
What is the pancragen dosage?
No dose is established. No independent trial exists, the studies used short courses, and a 20 mg vial is far larger than the microgram amounts given to animals.
Does pancragen work for type 1 diabetes?
No human data exist. The rat studies used streptozotocin to damage insulin-producing cells, and the human study enrolled people with type 2 diabetes.
What are the side effects of pancragen?
Unknown. No toxicology or pharmacokinetic studies were found, and the one human abstract reports no adverse events. If it lowers glucose, it could add to diabetes medicines.
Is pancragen FDA approved?
No. FDA has not approved it, it is not on FDA’s compounding-risk page and it is not in HHS’s October 2026 interim policy.
Is pancragen an amide or a free acid?
The 2007 rat study and a 2012 cell study name Lys-Glu-Asp-Trp-NH2, an amide. SwissChems lists the free-acid formula. Nobody has compared the two forms.
Is pancragen the same as PancraGEN?
No. PancraGEN is a molecular diagnostic test for pancreatic cysts. Pancragen is a research peptide.
Where can you buy pancragen?
SwissChems lists a 20 mg vial. Check that the certificate shows the lot number, identity by mass spectrometry and the end group of the peptide.
Is pancragen banned in sport?
Yes. WADA’s 2026 List bans any substance without regulatory approval under S0, which covers pancragen.
Keep researching: the Khavinson peptides guide, Vesugen, Pinealon, the full list of peptides and bioregulator capsules.
References
Show references (15)Hide references
- Zakutskii AN, et al. The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissue culture in young and old rats. Adv Gerontol 2006. Source
- Kvetnoi IM, et al. Effect of tetrapeptide pancragene on functional morphology of the pancreas in rats with experimental diabetes mellitus. Bull Exp Biol Med 2007. Source
- Khavinson VKh, et al. Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus. Bull Exp Biol Med 2007. Source
- Korkushko OV, Khavinson VKh, et al. Prospects of using pancragen for correction of metabolic disorders in elderly people. Bull Exp Biol Med 2011. Source
- Khavinson VKh, et al. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med 2012. Source
- Khavinson VKh, et al. Tetrapeptide stimulates functional activity of the pancreatic cells in aging. Adv Gerontol 2012. Source
- Khavinson VKh, et al. Effects of pancragen on the differentiation of pancreatic cells during their ageing. Bull Exp Biol Med 2013. Source
- Goncharova ND, et al. Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys. Adv Gerontol 2014. Source
- Goncharova ND, et al. Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys. Adv Gerontol 2015. Source
- Swiss Chems. Pancragen, 20mg: product page. Source
- ClinicalTrials.gov search for pancragen: no registered trials. Source
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (content dated 22 April 2026). Source
- BakerHostetler. HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. 28 October 2026. Source
- WADA. The 2026 Prohibited List. Source
- Khavinson VK, et al. Peptide regulation of gene expression: a systematic review. Molecules 2021. Source
